"With the availability of the newer selective serotonin reuptake inhibitors (SSRis), concern over a 'cholinergie rebound' seemed unnecessary since these agents demonstrate little or no anticholinergic activity. However, a review of the literature indicates that there may be other withdrawal symptoms associated with discontinuation of the SSRis. The time course and, perhaps to a lesser extent, the frequency of these symptoms appear to be correlated with the elimination half-lives of the agents."
Endow RA, Gutierrez MA, Wincor MZ. Is there any risk of a withdrawal syndrome associated with abrupt discontinuation of selective serotonin reuptake inhibitors? Calif Pharmacist. 1996;43:26-27.
California Pharmacists Association